Wall Street has so far dealt with a mixed second-quarter report card for biotechnology companies, but shares continue outpacing the broader market on a mix of positive sales results and a bright outlook for buyout potential within the sector.
Biotechnology company Celgene Corp. raised its full-year profit and revenue outlook Thursday after reporting a surge in second-quarter sales from its key cancer drug Revlimid.
Friday, 11 Jul 2008 | Source: The Associated Press
Drug company sales representatives will have to stop doling out coffee mugs and pens that push their products when they visit doctor's offices. But they can still sneak in the occasional free lunch.
What's the best sector for improving your stock portfolio near-term? Jeff Krumpleman of Fifth Third Asset Management thinks it's health care, and he has some specific selections that back him up.
The buyout offer from Swiss drug giant Roche has shares of DNA trading at their highest level in about two-and-a-half years and according to CNBC stock-stat maven, Robert Hum, if they close up at least 8.88% it'll be their biggest one-day percentage gain since April 15, 2005... Read More